Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 126
Summary
- Conditions
- Mesothelioma
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The purpose of this study is to find out what effects a new drug, pembrolizumab has on this type of cancer and if it can offer better results than standard pemetrexed and platinum-based chemotherapy alone. This study will also look at side effects and how the treatments impact quality of life
The purpose of this study is to find out what effects a new drug, pembrolizumab has on this type of cancer and if it can offer better results than standard pemetrexed and platinum-based chemotherapy alone. This study will also look at side effects and how the treatments impact quality of life
Tracking Information
- NCT #
- NCT02784171
- Collaborators
- National Cancer Institute, Naples
- Merck Sharp & Dohme Corp.
- Intergroupe Francophone de Cancerologie Thoracique
- Investigators
- Study Chair: Quincy Chu Cross Cancer Institute, Edmonton Alberta Canada Study Chair: Francesco Perrone National Cancer Institute of Naples, Italy Study Chair: Laurent Greillier Marseille Hopital Nord, France
Get Well Soon